Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Read More
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Read More
Considerations for Platinum-based Therapy
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Read More
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Read More
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Read More
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Read More
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Read More
Overview of Current mCRC Treatment Landscape
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Read More
Metastatic Colorectal Cancer: Future Directions in Care
Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.
Read More
Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials
Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.
Read More
Combination IO/TKI Strategies in Metastatic Colorectal Cancer
A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.
Read More
Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy
A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Read More
Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer
Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.
Read More
Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer
Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.
Read More
Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial
Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial
Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
Importance of Identifying HER2 Status in Metastatic Colorectal Cancer
Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.
Read More
Role of Tucatinib in HER2+ mCRC
Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.
Read More
HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates
Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.
Read More
Trastuzumab Deruxtecan in HER2+ mCRC
Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.
Read More
First-Line Treatment Options for mCRC
After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.
Read More